According to the listing by Moderna for its mRNA-2173 COVID-19 vaccine in the US government clinical trial registry, the company has been given approval for final (Phase 3) trials in 30,000 healthy volunteers starting 27 July.
The upcoming trials in 30,000 volunteers in a real-world setting will give experts a comprehensive look at its effectiveness and feasibility.
Since the first recorded use of ‘immunization’ in humans to prevent smallpox (in 1796), the development and scope of vaccines have seen some, incremental progress. New technology in development – messenger RNA vaccines – holds the potential to disrupt the entire approach to vaccine development.
Read more at Firstpost